CagriSema vs Retatrutide (2026): Next-Gen Obesity Drugs Compared
CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg, Novo Nordisk) vs Retatrutide (retatrutide (LY3437943), Eli Lilly)
Last verified November 2026
The verdict
CagriSema and retatrutide are two of the most advanced next-generation obesity therapies, but neither is FDA-approved and cross-trial comparisons have significant limitations. In the phase 3 REDEFINE-1 trial, CagriSema produced a mean weight loss of 20.4% at 68 weeks (treatment-policy estimand, N=2108); in retatrutide's phase 3 TRIUMPH-1 trial (NEJM 2026), adults without diabetes lost 23.7% on 9 mg and 25.0% on 12 mg at 80 weeks versus 3.9% on placebo. The trials differ in length, populations and estimands, so the numbers cannot be compared directly. CagriSema is further along the regulatory path: Novo Nordisk submitted it to the FDA in December 2025 based on REDEFINE 1 and 2 and expects a decision by late 2026, while Lilly plans to submit retatrutide in the first quarter of 2027. CagriSema also has a head-to-head result against tirzepatide, REDEFINE 4, in which it did not show non-inferiority (the full REDEFINE program). Our TRIUMPH phase 3 update tracks the retatrutide trials; no head-to-head trial of these two drugs exists.
Side-by-side comparison
| Field | CagriSema | Retatrutide |
|---|---|---|
| Peak weight loss (trial) | −20.4% at 68 wk (REDEFINE-1, treatment-policy estimand, N=2108) | −24.2% at 48 wk (Phase 2, 12 mg dose, N=81 in that arm) |
| Mechanism | Amylin analog (cagrilintide) + GLP-1 receptor agonist (semaglutide) | Triple agonist: GLP-1, GIP, and glucagon receptors |
| Trial stage / status | Phase 3 complete; submitted to the FDA in December 2025, decision expected by late 2026 | TRIUMPH-1 and TRIUMPH-2 published 2026; BLA submission planned Q1 2027 |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| FDA status | Not approved; under FDA review since the December 2025 submission | Not approved; Phase 3 ongoing, earliest approval 2027–2028 |
| GI side effects | Reported in 79.6% of CagriSema group (nausea, vomiting, diarrhea; mostly mild–moderate) | Dose-related GI events predominated in Phase 2; largely mild–moderate |
| Cardiovascular / CVOT data | REDEFINE-1 not a cardiovascular outcomes trial; dedicated CVOT ongoing | No CVOT data available; TRIUMPH cardiovascular outcomes arm not yet reported |
Frequently asked questions
Is CagriSema or retatrutide more effective for weight loss?
Based on available trial data, retatrutide showed 24.2% mean weight loss in a Phase 2 trial (48 weeks, 12 mg, N=81), while CagriSema showed 20.4% in the Phase 3 REDEFINE-1 trial (68 weeks, N=2108). These are not comparable figures — different trial phases, sample sizes, and durations make a direct conclusion unreliable. Retatrutide's phase 3 TRIUMPH-1 trial (NEJM 2026) has since reported 23.7% (9 mg) and 25.0% (12 mg) at 80 weeks versus 3.9% on placebo, but without a head-to-head trial no advantage can be confirmed.
When will CagriSema be FDA approved?
Novo Nordisk submitted CagriSema to the FDA in December 2025 based on the REDEFINE 1 and REDEFINE 2 trials and says it expects a decision by late 2026, though regulatory timelines are not guaranteed. CagriSema was not approved anywhere as of late October 2026.
When will retatrutide be available?
Retatrutide (LY3437943) has published phase 3 results (TRIUMPH-1 and TRIUMPH-2, 2026), and Eli Lilly plans to submit a Biologics License Application to the FDA in the first quarter of 2027, so launch depends on that review. It is currently available only through registered clinical trials — search clinicaltrials.gov for the TRIUMPH program.
How do CagriSema and retatrutide work differently?
CagriSema combines two drugs: cagrilintide (an amylin analog that reduces appetite and slows gastric emptying) and semaglutide (a GLP-1 receptor agonist). Retatrutide is a single molecule that activates three hormone receptors simultaneously — GLP-1, GIP, and glucagon. The glucagon component may amplify energy expenditure, a mechanism absent in CagriSema.
Is retatrutide better for type 2 diabetes than CagriSema?
No direct comparison exists. CagriSema has Phase 3 data in T2D (REDEFINE-2, NEJM 2025, PMID 40544432) showing 13.7% weight loss at 68 weeks in that population. Retatrutide's glucagon component could complicate glucose control in T2D, though Phase 2 data showed favorable glycemic effects overall. Neither is approved for T2D as of November 2026.
Can I participate in a clinical trial for these drugs?
Yes. ClinicalTrials.gov lists ongoing TRIUMPH trials for retatrutide (NCT numbers within the TRIUMPH program) and any remaining REDEFINE trials for CagriSema. Eligibility typically requires a BMI of 30 or higher, or 27+ with a weight-related complication. Discuss with your physician whether you qualify.
References
- 1.Garvey WT, Blüher M, et al.; REDEFINE 1 Study Group Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity N Engl J Med. 2025. PMID: 40544433.
- 2.Jastreboff AM, Kaplan LM, Frías JP, et al.; Retatrutide Phase 2 Obesity Trial Investigators Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial N Engl J Med. 2023. PMID: 37366315.
- 3.Giblin K, Bethel MA, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials Diabetes Obes Metab. 2026. PMID: 41090431.
- 4.Davies MJ, et al.; REDEFINE 2 Study Group Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes N Engl J Med. 2025. PMID: 40544432.
- 5.Jastreboff AM, Kaplan LM, Davies MJ, et al.; TRIUMPH-1 Investigators Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity N Engl J Med. 2026. PMID: 42814954.
- 6.Eli Lilly and Company Lilly reports second-quarter 2026 financial results (Form 8-K exhibit) U.S. Securities and Exchange Commission. 2026. https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm
- 7.Novo Nordisk A/S CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved Novo Nordisk company announcement. 2026. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916501
Related comparisons
- Wegovy vs Zepbound
- Ozempic vs Mounjaro
- Semaglutide vs Tirzepatide
- Rybelsus vs Ozempic
- Mounjaro vs Zepbound
- Foundayo vs Rybelsus
See the full drug-vs-drug verdict index or provider rankings.